Published in Bull Soc Pathol Exot on December 01, 1999
Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet (1996) 3.40
Sequence variations in the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene and their relationship with pyrimethamine resistance. Mol Biochem Parasitol (1998) 2.08
Nitric oxide in cerebral malaria. J Infect Dis (1994) 1.64
In vitro activity of antimalarials against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon. Am J Trop Med Hyg (1996) 1.55
Desipramine or cyproheptadine for reversing chloroquine resistance? Lancet (1990) 1.52
Amodiaquine remains effective for treating uncomplicated malaria in west and central Africa. Trans R Soc Trop Med Hyg (2000) 1.51
High levels of circulating IL-10 in human malaria. Clin Exp Immunol (1994) 1.41
Analysis of the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene sequence. Gene (1998) 1.37
In vitro antimalarial activity of limonoids from Khaya grandifoliola C.D.C. (Meliaceae). J Ethnopharmacol (2000) 1.37
Kinetic properties of dihydrofolate reductase from wild-type and mutant Plasmodium vivax expressed in Escherichia coli. Mol Biochem Parasitol (2001) 1.28
Molecular basis of in vivo resistance to sulfadoxine-pyrimethamine in African adult patients infected with Plasmodium falciparum malaria parasites. Antimicrob Agents Chemother (1998) 1.28
Sequence variations in the genes encoding dihydropteroate synthase and dihydrofolate reductase and clinical response to sulfadoxine-pyrimethamine in patients with acute uncomplicated falciparum malaria. J Infect Dis (2000) 1.22
Comparison of in vivo and in vitro tests of resistance in patients treated with chloroquine in Yaoundé, Cameroon. Bull World Health Organ (1999) 1.21
Analysis of the key pfcrt point mutation and in vitro and in vivo response to chloroquine in Yaoundé, Cameroon. J Infect Dis (2001) 1.20
In vitro activity of lumefantrine (benflumetol) against clinical isolates of Plasmodium falciparum in Yaoundé, Cameroon. Antimicrob Agents Chemother (1998) 1.20
Efficacy of oral pyronaridine for the treatment of acute uncomplicated falciparum malaria in African children. Clin Infect Dis (1998) 1.12
Kinetics of lymphocyte subsets from peripheral blood during a Plasmodium falciparum malaria attack. Clin Exp Immunol (1992) 1.09
In vitro activities of pyronaridine, alone and in combination with other antimalarial drugs, against Plasmodium falciparum. Antimicrob Agents Chemother (1999) 1.07
False chloroquine resistance in Africa. Lancet (1997) 1.06
Isotypic analysis of maternally transmitted Plasmodium falciparum-specific antibodies in Cameroon, and relationship with risk of P. falciparum infection. Clin Exp Immunol (1997) 1.06
Molecular epidemiology of malaria in Yaoundé, Cameroon. III. Analysis of chloroquine resistance and point mutations in the multidrug resistance 1 (pfmdr 1) gene of Plasmodium falciparum. Am J Trop Med Hyg (1998) 1.05
Molecular epidemiology of malaria in Yaounde, Cameroon. VI. Sequence variations in the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene and in vitro resistance to pyrimethamine and cycloguanil. Am J Trop Med Hyg (2000) 1.03
Immune response to Plasmodium falciparum liver stage antigen-1: geographical variations within Central Africa and their relationship with protection from clinical malaria. Trans R Soc Trop Med Hyg (2000) 1.02
Plasmodium falciparum: detection of P-glycoprotein in chloroquine-susceptible and chloroquine-resistant clones and isolates. Exp Parasitol (1995) 1.02
Immune responses against Plasmodium falciparum asexual blood-stage antigens and disease susceptibility in Gabonese and Cameroonian children. Am J Trop Med Hyg (1999) 1.01
[Surveillance of falciparum malaria susceptibility to antimalarial drugs and policy change in the Comoros]. Bull Soc Pathol Exot (2007) 1.01
Immune response to Plasmodium falciparum antigens in Cameroonian primigravidae: evolution after delivery and during second pregnancy. Clin Exp Immunol (1997) 1.00
Chloroquine-potentiating action of antihistaminics in Plasmodium falciparum in vitro. Ann Trop Med Parasitol (1991) 1.00
Plasmodium falciparum: detection of antifolate resistance by mutation-specific restriction enzyme digestion. Exp Parasitol (1995) 1.00
Site-based study on polymorphism of Plasmodium falciparum MSP-1 and MSP-2 genes in isolates from two villages in Central Africa. Parassitologia (2000) 1.00
In vitro activity of dihydroartemisinin against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon. Am J Trop Med Hyg (1999) 0.99
Malaria cellular immune responses in neonates from Cameroon. Parasite Immunol (1996) 0.99
In vitro culture and drug sensitivity assay of Plasmodium falciparum with nonserum substitute and acute-phase sera. J Clin Microbiol (1999) 0.99
[Malaria in health centres in the southern districts of Brazzaville, Congo]. Bull Soc Pathol Exot (2008) 0.97
Chemoresistance of P. falciparum in urban areas of Yaounde, Cameroon. Part 1: Surveillance of in vitro and in vivo resistance of Plasmodium falciparum to chloroquine from 1994 to 1999 in Yaounde, Cameroon. Trop Med Int Health (2000) 0.95
Chemoresistance of Plasmodium falciparum in the urban region of Yaounde, Cameroon. Part 2: Evaluation of the efficacy of amodiaquine and sulfadoxine-pyrimethamine combination in the treatment of uncomplicated Plasmodium falciparum malaria in Yaounde, Cameroon. Trop Med Int Health (2000) 0.95
Molecular epidemiology of malaria in Yaounde, Cameroon II. Baseline frequency of point mutations in the dihydropteroate synthase gene of Plasmodium falciparum. Am J Trop Med Hyg (1998) 0.93
[Surveillance of the in vivo sensitivity of Plasmodium falciparum to antimalarial agents: the results of initial tests of the OCEAC Malaria Network]. Med Trop (Mars) (1997) 0.92
Molecular epidemiology of malaria in Yaounde, Cameroon IV. Evolution of pyrimethamine resistance between 1994 and 1998. Am J Trop Med Hyg (1999) 0.92
Molecular epidemiology of malaria in Yaounde, Cameroon. VII. Analysis of recrudescence and reinfection in patients with uncomplicated falciparum malaria. Am J Trop Med Hyg (2001) 0.91
Clinical efficacy and pharmacokinetics of micronized halofantrine for the treatment of acute uncomplicated falciparum malaria in nonimmune patients. Am J Trop Med Hyg (1994) 0.91
Plasma levels of TNF-alpha soluble receptors correlate with outcome in human falciparum malaria. Eur Cytokine Netw (1994) 0.91
Detection of Plasmodium ovale malaria parasites by species-specific 18S rRNA gene amplification. Mol Cell Probes (1997) 0.90
Heterogeneity in the circumsporozoite protein gene of Plasmodium malariae isolates from sub-Saharan Africa. Mol Biochem Parasitol (1998) 0.90
Monitoring of the therapeutic efficacy of chloroquine for the treatment of uncomplicated, Plasmodium falciparum malaria in Iran. Ann Trop Med Parasitol (2006) 0.90
Association between antifol resistance in vitro and DHFR gene point mutation in Plasmodium falciparum isolates. Trans R Soc Trop Med Hyg (1996) 0.90
Diagnosis of Plasmodium malariae infection by the polymerase chain reaction. Trans R Soc Trop Med Hyg (1997) 0.88
Molecular epidemiology of malaria in Yaounde, Cameroon. VIII. Multiple Plasmodium falciparum infections in symptomatic patients. Am J Trop Med Hyg (2001) 0.88
Relationships between malaria prevalence and malaria-related morbidity in school children from two villages in central Africa. Am J Trop Med Hyg (1999) 0.88
[Plasmodium falciparum chemoresistance. The situation in Africa in 1989]. Med Trop (Mars) (1990) 0.88
In-vitro activity of primaquine against the asexual blood stages of Plasmodium falciparum. Ann Trop Med Parasitol (1999) 0.88
In vitro activities of novel catecholate siderophores against Plasmodium falciparum. Antimicrob Agents Chemother (1996) 0.87
Type RI resistance to halofantrine in West Africa. Trop Med Parasitol (1991) 0.87
Evaluating the efficacy of chloroquine in febrile Guinean children infected with Plasmodium falciparum by a simplified in vivo test. Bull World Health Organ (1992) 0.87
In vitro and in vivo potentiation of chloroquine against malaria parasites by an enantiomer of amlodipine. Antimicrob Agents Chemother (1991) 0.87
Plasma concentrations of the enantiomers of halofantrine and its main metabolite in malaria patients. Eur J Clin Pharmacol (1994) 0.86
Short report: effects of pyronaridine on gametocytes in patients with acute uncomplicated falciparum malaria. Am J Trop Med Hyg (1999) 0.86
pfmdr1 gene mutation and clinical response to chloroquine in Yaoundé, Cameroon. Trans R Soc Trop Med Hyg (1997) 0.86
Molecular epidemiology of malaria in Yaounde, Cameroon I. Analysis of point mutations in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Am J Trop Med Hyg (1998) 0.85
Cardiac effects of amodiaquine and sulfadoxine-pyrimethamine in malaria-infected African patients. Am J Trop Med Hyg (2001) 0.85
Evolution of chloroquine resistance in central and west Africa. Trop Med Parasitol (1993) 0.84
Assessment of three in vitro tests and an in vivo test for chloroquine resistance in Plasmodium falciparum clinical isolates. J Clin Microbiol (1998) 0.84
[Drug-resistant malaria: problems with its definition and technical approaches]. Sante (2000) 0.83
Assessment of pyronaridine activity in vivo and in vitro against the hepatic stages of malaria in laboratory mice. Trans R Soc Trop Med Hyg (2000) 0.82
[Stability of P. Falciparum resistance to chloroquine between 1987 and 1989 in Mounana, Gabon]. Bull World Health Organ (1992) 0.82
DHFR gene point mutation as a predictor of Plasmodium falciparum resistance to cycloguanil in malaria cases from Africa imported to France. Trans R Soc Trop Med Hyg (1997) 0.82
Pyronaridine for treatment of Plasmodium ovale and Plasmodium malariae infections. Antimicrob Agents Chemother (1997) 0.81
Halofantrine resistance in African countries. Lancet (1993) 0.80
Susceptibility of African isolates of Plasmodium falciparum to artemisinin (qinghaosu). Trop Med Parasitol (1992) 0.80
Reduced in vitro susceptibility to halofantrine of Plasmodium falciparum in West Africa. Lancet (1990) 0.80
Resistant malaria in children. Indian Pediatr (2001) 0.80
Chronotherapy of malaria: improved efficacy of timed chloroquine treatment of patients with Plasmodium falciparum infections. Trans R Soc Trop Med Hyg (1992) 0.79
Evaluation of a new sulfadoxine sensitivity assay in vitro for field isolates of Plasmodium falciparum. Trans R Soc Trop Med Hyg (2001) 0.79
Chloroquine resistance in Plasmodium falciparum and polymorphism of the CG2 gene. J Infect Dis (1999) 0.78
Monitoring antimalarial drug efficacy. Clin Infect Dis (2004) 0.78
Plasmodium vivax: rapid detection by polymerase chain reaction and restriction fragment length polymorphism of the key mutation in dihydrofolate reductase-thymidylate synthase gene associated with pyrimethamine resistance. Exp Parasitol (1998) 0.78
Absence of effect of retinol on the in vitro development of Plasmodium falciparum. Int J Vitam Nutr Res (1992) 0.77
Sulfadoxine-pyrimethamine for uncomplicated falciparum malaria: treatment failure and resistance in Malawi remain subject for debate. BMJ (2004) 0.77
Uptake of mefloquine enantiomers into uninfected and malaria-infected erythrocytes. Drug Metab Dispos (1996) 0.77
Use of a semi-nested PCR diagnosis test to evaluate antifolate resistance of Plasmodium falciparum isolates. Mol Cell Probes (1995) 0.77
[Failure of chemoprevention with mefloquine in western Africa]. Presse Med (1990) 0.77
[In vivo evaluation of sulfadoxine-pyrimethamine efficacy during uncomplicated falciparum malaria in children of Yopougon (Abidjan, Côte d'Ivoire)]. Bull Soc Pathol Exot (2004) 0.77
In vitro activity of cycloguanil against African isolates of Plasmodium falciparum. Antimicrob Agents Chemother (1993) 0.77
[The role of nitric oxide in cerebral malaria]. Med Trop (Mars) (1995) 0.77
In vivo-in vitro test for chloroquine potentiation by cyproheptadine against Plasmodium falciparum. Trans R Soc Trop Med Hyg (1991) 0.76
In vitro susceptibility of Plasmodium falciparum to monodesethylamodiaquine, quinine, mefloquine and halofantrine in Abidjan (Côte d'Ivoire). Afr Health Sci (2010) 0.76
[Comparative study of artemether and quinine in severe Plasmodium falciparum malaria in adults and older children in Cameroon]. Med Trop (Mars) (1999) 0.76
Molecular epidemiology of malaria in Yaounde, Cameroon V. analysis of the omega repetitive region of the plasmodium falciparum CG2 gene and chloroquine resistance. Am J Trop Med Hyg (1999) 0.76
Amodiaquine as the first-line treatment of malaria in Yaoundé, Cameroon: presumptive evidence from activity in vitro and cross-resistance patterns. Trans R Soc Trop Med Hyg (1998) 0.76
Point mutations in the Plasmodium falciparum cg2 gene, polymorphism of the kappa repeat region, and their relationship with chloroquine resistance. Trans R Soc Trop Med Hyg (2001) 0.75
Inefficacy of amodiaquine against chloroquine-resistant malaria. Lancet (1991) 0.75
Confused malaria chemoprophylaxis. Lancet (1994) 0.75
Antimalarial chemoprophylaxis for west Africa. Lancet (1993) 0.75